The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.

<h4>Background</h4>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) provides antifilarial medications to hundreds of millions of people annually to treat filarial infections and prevent elephantiasis. Recent trials have shown that a single-dose, triple-drug treatment (iverm...

Full description

Bibliographic Details
Main Authors: Gary J Weil, Joshua Bogus, Michael Christian, Christine Dubray, Yenny Djuardi, Peter U Fischer, Charles W Goss, Myra Hardy, Purushothaman Jambulingam, Christopher L King, Vijesh Sridhar Kuttiat, Kaliannagounder Krishnamoorthy, Moses Laman, Jean Frantz Lemoine, Katiuscia K O'Brian, Leanne J Robinson, Josaia Samuela, Kenneth B Schechtman, Anita Sircar, Adinarayanan Srividya, Andrew C Steer, Taniawati Supali, Swaminathan Subramanian, DOLF IDA Safety Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-06-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1002839

Internet

https://doi.org/10.1371/journal.pmed.1002839

Similar Items